Novel Redirected T–Cell Immunotherapies for Advanced Prostate Cancer

Immunotherapy has failed to achieve durable remissions in advanced prostate cancer patients. More potent T-cell–redirecting strategies may be needed to overcome the immunologically exclusive and suppressive tumor microenvironment. Clinical trials are underway, seeking to define the optimal target fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Dorff, Tanya B., Narayan, Vivek, Forman, Stephen J., Zang, Peter D., Fraietta, Joseph A., June, Carl H., Haas, Naomi B., Priceman, Saul J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8866199/
https://www.ncbi.nlm.nih.gov/pubmed/34675084
http://dx.doi.org/10.1158/1078-0432.CCR-21-1483

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8866199/
https://www.ncbi.nlm.nih.gov/pubmed/34675084
http://dx.doi.org/10.1158/1078-0432.CCR-21-1483

Ejemplares similares